NCT07185022View on ClinicalTrials.gov

Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion

NANot yet recruitingINTERVENTIONAL
Enrollment

282

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

February 1, 2030

Study Completion Date

May 1, 2030

Conditions
StrokeCerebrovascular DisordersBrain DiseasesNervous System DiseasesVascular DiseasesIschemic StrokeInfarctionMedium Vessel Occlusion
Interventions
PROCEDURE

Intra-arterial Thrombolysis

rhTNK-tPA（Tenecteplase）dose: 0.4 - 0.8 mg/min, maximum dose: 16mg.

DRUG

Best Medical Treatment

Patients in this group will receive standard medical therapy in accordance with the guideline-directed management for acute ischemic stroke.

Trial Locations (1)

230031

The Second (Affiliated) Hospital of Anhui Medical University, Hefei

All Listed Sponsors
lead

The Second Hospital of Anhui Medical University

OTHER

NCT07185022 - Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion | Biotech Hunter | Biotech Hunter